Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective
Published 2016 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Cost-effectiveness analysis of exenatide once-weekly versus dulaglutide, liraglutide, and lixisenatide for the treatment of type 2 diabetes mellitus: an analysis from the UK NHS perspective
Authors
Keywords
-
Journal
JOURNAL OF MEDICAL ECONOMICS
Volume 19, Issue 12, Pages 1127-1134
Publisher
Informa UK Limited
Online
2016-06-17
DOI
10.1080/13696998.2016.1203329
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
- (2016) Sheena Kayaniyil et al. Diabetes Therapy
- A Network Meta-analysis Comparing Exenatide Once Weekly with Other GLP-1 Receptor Agonists for the Treatment of Type 2 Diabetes Mellitus
- (2016) Sheena Kayaniyil et al. Diabetes Therapy
- The Short-Term Cost-Effectiveness of Once-Daily Liraglutide Versus Once-Weekly Exenatide for the Treatment of Type 2 Diabetes Mellitus in the United States
- (2015) Bruce Wang et al. PLoS One
- Cost-Effectiveness Analysis Alongside Clinical Trials II—An ISPOR Good Research Practices Task Force Report
- (2015) Scott D. Ramsey et al. VALUE IN HEALTH
- The impact on utilities of differences in body weight among Canadian patients with type 2 diabetes
- (2014) S. Lane et al. CURRENT MEDICAL RESEARCH AND OPINION
- Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
- (2014) Silvio E. Inzucchi et al. DIABETES CARE
- Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial
- (2014) Michaela Diamant et al. Lancet Diabetes & Endocrinology
- UKPDS Outcomes Model 2: a new version of a model to simulate lifetime health outcomes of patients with type 2 diabetes mellitus using data from the 30 year United Kingdom Prospective Diabetes Study: UKPDS 82
- (2013) A. J. Hayes et al. DIABETOLOGIA
- Efficacy, Safety, and Tolerability of Exenatide Once Weekly in Patients With Type 2 Diabetes Mellitus: An Integrated Analysis of the DURATION Trials
- (2013) Michael Grimm et al. POSTGRADUATE MEDICINE
- The cost-effectiveness of exenatide once weekly compared with exenatide twice daily and insulin glargine for the treatment of patients with type two diabetes and body mass index ≥30 kg/m2in Spain
- (2013) Tiago Fonseca et al. JOURNAL OF MEDICAL ECONOMICS
- A network meta-analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide once daily in comparison with insulin glargine, exenatide twice daily or placebo
- (2012) D. A. Scott et al. DIABETES OBESITY & METABOLISM
- Estimating the current and future costs of Type 1 and Type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs
- (2012) N. Hex et al. DIABETIC MEDICINE
- Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study
- (2012) John B Buse et al. LANCET
- Long-term cost-utility analysis of exenatide once weekly versus insulin glargine for the treatment of type 2 diabetes patients in the US
- (2012) Yevgeniy Samyshkin et al. JOURNAL OF MEDICAL ECONOMICS
- Long-term cost-consequence analysis of exenatide once weekly vs sitagliptin or pioglitazone for the treatment of type 2 diabetes patients in the United States
- (2012) Anne-Laure Guillermin et al. JOURNAL OF MEDICAL ECONOMICS
- Encapsulation of Exenatide in Poly-(d,l-Lactide-Co-Glycolide) Microspheres Produced an Investigational Long-Acting Once-Weekly Formulation for Type 2 Diabetes
- (2011) Mary Beth DeYoung et al. Diabetes Technology & Therapeutics
- Interpreting Indirect Treatment Comparisons and Network Meta-Analysis for Health-Care Decision Making: Report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: Part 1
- (2011) Jeroen P. Jansen et al. VALUE IN HEALTH
- Cost-effectiveness of saxagliptin (Onglyza®) in type 2 diabetes in Sweden
- (2011) Ola Granström et al. Primary Care Diabetes
- Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in the UK
- (2011) Amélie Beaudet et al. JOURNAL OF MEDICAL ECONOMICS
- A population model evaluating the costs and benefits associated with different oral treatment strategies in people with type 2 diabetes
- (2010) P. McEwan et al. DIABETES OBESITY & METABOLISM
- Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 Diabetes
- (2010) Olivia J. Phung JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Transferability of Economic Evaluations Across Jurisdictions: ISPOR Good Research Practices Task Force Report
- (2009) Michael Drummond et al. VALUE IN HEALTH
- Costs of managing severe hypoglycaemia in three European countries
- (2009) Mette Hammer et al. JOURNAL OF MEDICAL ECONOMICS
- The cost of renal dialysis in a UK setting--a multicentre study
- (2008) K. Baboolal et al. NEPHROLOGY DIALYSIS TRANSPLANTATION
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started